ImmUniverse
Description
Immuniverse research projects at LCSB aim at to better control and treatment of immune-mediated diseases by exploring the universe of microenvironment-imposed tissue signatures and their correlates in liquid biopsies. The precise aims of the ImmUniverse project are given below:
Objective 1. Comprehensive molecular characterization of intestinal/dermal microenvironment and immune cell profiles that provides a data foundation for advanced bioinformatics, statistical and model-based analysis.
Objective 2. Confirmation of the identified signatures in tissue and blood samples from a large retrospective and longitudinal cohort and in a non-interventional prospective clinical study.
Objective 3. Evaluation of evolving technologies such as dermal open-flow microperfusion and ultrasound-enabled gut liquid biopsy as non-invasive approaches for the identification of new ―microinvasive‖ biomarkers suitable to reflect clinically relevant tissue-based signatures of disease progression and/or response to treatment.
Objective 4. Integrated large-scale data storage and computing platform to collect, curate, harmonize and standardize the newly and previously generated data.
Objective 5. Having included excellent SME partners and incorporating large industry partners, we will improve the competitiveness of European industry and support the development of biomarkers, which will benefit patients.
Accession number
ELU-1-0A6EF9-1
Project acronym
ImmUniverse
Project website
Start date
2020-01-01
End date
2024-12-31
Funding
IMI2 - Call 15 (Grant number 853995)
Types
Title | Primary purpose | Study type | Organism |
LUCENT-1 (NCT 03518086) | Lilly Lucent imaging in Ulcerative Colitis |
C71104
|
|
204869 Phase 2a/b in Ulcerative Colitis | 204869 Phase 2a/b in Ulcerative Colitis |
C71104
|
|
Pfizer (NCT02958865) | Pfizer |
C71104
NCT02958865
|
|
AMCUC study | AMCUC study |
C71104
|
|
203167 Phase 2a in Psoriasis | 203167 Phase 2a in Psoriasis |
C71104
|
|
TREATgermany | TREATgermany |
|
|
P2N ADPSOKO | P2N ADPSOKO |
|
|